All News
Did you know that the first virus, the tobacco mosaic virus, was described in 1892? @AdamJBrownMD gave a fascinating lecture today regarding that included the history of viruses. #ACR22 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
Ab0577 #ACR22 Sao Paulo Aging & Health (SPAH)
Radius 1/3 BMD enhance fx risk estimates when combined w/ spine (RR 1.4, p=0.03)
For radius+hip or radius+spine/hip, radius DEXA is non-significant - only hip predicted fx
Use radius BMD when hip unattainable- THA/severe OA
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Save the date! RheumNow Live is back on 3/18-3/19 in Dallas, Texas.
Register now!
https://t.co/tgce0Mydeh
#RNL23 #ACR22 https://t.co/XI6hcxuNEn
Links:
Dr. John Cush RheumNow ( View Tweet)
Do you know the 3 types of Y. Pestis plague? @AdamJBrownMD reviews the Bubonic, Pneumonic, and Septicemia plagues at #ACR22 @RheumNow. Most recently, there was an outbreak of Pneumonic plague in Madagascar in the 2010s!
Dr. Rachel Tate uptoTate ( View Tweet)
MEFV mutation protected against the plague. Protected against deactivation of inflammasome by yersinia pestis.
@RheumNow #ACR22 #rheuminations https://t.co/OqBay6Svdb
Julian Segan JulianSegan ( View Tweet)
GM-CSF/mavrilimumab in GCA masterclass from Maria Cid this morning.
Sadly, as John Stone & Sharon Chung ask and Maria Cid reflects on, we're not sure what happens next, despite the promising phase 2 & elegant MOA.
No current plans for a mavrilimumab GCA phase 3
#ACR22 @RheumNow https://t.co/c5PSqnFnC2
David Liew drdavidliew ( View Tweet)
Ab0574 #ACR22: Osteoporosis in Men - Under-recognized? Under-Screened? Under-Diagnosed!
@AMollaeianMD: Retrosp study >65 yo
<1% M have DEXA compared to 7-10% in F in 2010, 2018, and 2021
Hip fx 4.1% F, 3% M
DEXA declined in M between 2010-2018, no change in 2021
🦴🦴🩻
@RheumNow https://t.co/LbmxLnIX1Q
Eric Dein ericdeinmd ( View Tweet)
How to prescribe methotrexate in a post-Roe era:
Abstract #L09
💊 6% of > 1,700 patients reported access issues to MTX
-63% had a delay in filling script
🤰Excessive questions about possibility of pregnancy
🧑⚕️Pharmacy refused to fill
#ACR22 #ACRbest @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
#ACR22 Abstr#0799 Is Evusheld effective in patients on B-cell depleting therapies? Early data (Jan-May 22) from @CCalabreseDO @LCalabreseDO are encouraging: 13/417 (3%) breakthrough infection in fully vac pts, 1 hospitalised. More data needed for Omicron subvariants @RheumNow https://t.co/g4Y1IMO67X
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #ACR22 Annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its Faculty
Dr. John Cush RheumNow ( View Tweet)
#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed:
Breakthrough infection 30% mostly mild; Severe 4%; 1 death
Poor outcomes predicted by comorbidities & low IgG
Risk reduced by 50% with each vac dose
OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
☝️Remember: Not all skin thickening is SSc!
🔸Lipodermatosclerosis is a differential. Has an inverted champagne bottle appearance - caused by venous stasis and venous HTN
#ACR22 @RheumNow #Scleroderma #RheumTwitter https://t.co/joWWn6BnVC
sheila RHEUMarampa ( View Tweet)
Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY
Richard Conway RichardPAConway ( View Tweet)
Lanz et al. Inverse relationship between number of ACPAs and subclinical ILD. Effect appears confined to African American and Hispanic participants. Not sure what to make of this at all. @RheumNow #ACR22 Abstr#1203 https://t.co/Ok3PCLFyxe https://t.co/UHlI6HOUmc
Richard Conway RichardPAConway ( View Tweet)
Deodhar et al. Bimekizumab (IL-17A/Fi) in nr-axSpA. Efficacy shown across all outcomes. Confirms bimekizumab works across spectrum of axSpA (not surprisingly). @RheumNow #ACR22 Abstr#0544 https://t.co/XVGBgBQpTH https://t.co/39zW5Ex9xh
Richard Conway RichardPAConway ( View Tweet)
Hanlon @MeganHanlon4 @dougveale et al. Loss of macrophage homeostasis occurs in pre-RA, and appears to be an early factor in RA development
@RheumNow #ACR22 Abstr#0554 https://t.co/UL1jVGVlrA https://t.co/i1WWQlHs2m
Richard Conway RichardPAConway ( View Tweet)
Proft @ProftDr et al. NSAIDs+golimumab no better than golimumab monotherapy in reducing spinal progression in AS. But... for high risk patients there may be some benefit - see figure. @RheumNow #ACR22 Abstr#0546 https://t.co/xo9Uy6aX71 https://t.co/vZgaoeEQn4
Richard Conway RichardPAConway ( View Tweet)
Weinstein et al. GO-BACK. Another TNFi withdrawal study in nr-axSpA. Again showing it doesn't work. 12 months. Only 34% of withdrawal group in remission vs 84% full dose and 68% reduced dose group. @RheumNow #ACR22 Abstr#0545 https://t.co/Fa5YgT9FYk https://t.co/9C8ShI9qjk
Richard Conway RichardPAConway ( View Tweet)
Day 2: Tips to avoid burnout. I know it’s Sunday morning but a dose of #physicalactivity will keep the mind and body sane. Dare to accept challenge? #ACRVirtual5K Run #ACR22 #rheumatologyrunners #wellbeing #foggy @RheumNow #RheumPix https://t.co/N9ulz8KPVw
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Broder et al. HCQ alone vs steroid alone as maintenance in ESKD due to SLE. HCQ less cardiac events, less infection. @RheumNow #ACR22 Abstr#0539 https://t.co/mb3Eof2Uiv https://t.co/3i3ZTY25ru
Richard Conway RichardPAConway ( View Tweet)